Clinical Guides
Chikungunya
A clinically focused Indian guide to phase-specific recognition, laboratory confirmation, supportive care and follow-up of chikungunya, with explicit dengue exclusion and prescribing safeguards.
MedNext Academy | 14 min read
Chikungunya
A clinically focused Indian guide to phase-specific recognition, laboratory confirmation, supportive care and follow-up of chikungunya, with explicit dengue exclusion and prescribing safeguards.
Summary
Chikungunya is an acute mosquito-borne illness caused by chikungunya virus, an alphavirus transmitted principally by infected Aedes mosquitoes. Abrupt fever and prominent bilateral arthralgia or arthritis are the characteristic clinical pairing, often accompanied by headache, myalgia, rash or joint swelling. The name must not become a shortcut for every monsoon fever with body pain: dengue, malaria, leptospirosis, scrub typhus, enteric fever and bacterial sepsis can overlap, and more than one infection can occur. Severe disease is uncommon but possible, particularly at the extremes of age, around delivery and in people with major comorbidity.
Illness is best understood in phases. The acute febrile period usually occupies the first days; a post-acute period may contain continuing pain, stiffness and functional limitation; symptoms lasting beyond three months constitute a chronic phase in the NCVBDC framework. Persistent symptoms are real but heterogeneous. Some patients have inflammatory synovitis, while others have mechanical pain, neuropathic features, deconditioning or an unrelated rheumatic disorder. Reassessment is safer than automatically escalating analgesics or immunosuppression.
There is no specific antiviral treatment established for routine chikungunya care. Acute management is supportive, with oral hydration when feasible, paracetamol-based symptom relief and deliberate avoidance of NSAIDs while dengue remains possible. Confirmed post-acute inflammatory disease may justify different treatment after bleeding, renal, gastrointestinal, pregnancy and cardiovascular risks are checked. Mosquito-bite prevention during the first week helps interrupt human-mosquito-human transmission. This educational draft is reviewed and has been reviewed by the MedNext Clinical Team; it does not replace individual assessment or local outbreak instructions.
How Common Is It?
Chikungunya distribution is dynamic because competent Aedes vectors, population immunity, viral introduction, climate, water storage, urbanisation and surveillance performance vary. India experienced re-emergence in the twenty-first century and continues to report cases and outbreaks across multiple states and union territories. The NCVBDC 2023 guideline described endemicity across most Indian jurisdictions and a large sentinel laboratory network, but those statements are a dated programme snapshot rather than a current patient-level probability. State bulletins and local Integrated Health Information Platform or outbreak reports should guide situational awareness.
Reported counts substantially understate infection when mild cases do not seek care, testing is unavailable, or fever is classified clinically. Conversely, hospital series enrich for older, comorbid or atypically severe patients and cannot estimate community risk. IgM may remain detectable after the acute illness, so a positive result is not automatically a newly acquired case without illness timing and compatible symptoms. Changing test access can create an apparent rise that partly represents improved ascertainment. A national count without a stated case definition, denominator and reporting period is therefore misleading.
WHO described chikungunya transmission in well over one hundred countries by 2025 and emphasized that arboviral syndromes are difficult to distinguish clinically where viruses co-circulate. For practice, prevalence should influence but never replace differential diagnosis. During an Aedes-borne outbreak, fever plus disabling polyarthralgia makes chikungunya plausible; shock, mucosal bleeding, progressive abdominal symptoms, profound lethargy or rising haematocrit must still trigger a dengue pathway. Local audit should track suspected and laboratory-confirmed cases separately, illness day at sampling, admissions, organ complications, referral delay and persistent functional disability.
Risk Factors
Risk begins with exposure to Aedes mosquitoes in an area where chikungunya virus is circulating. Aedes aegypti commonly breeds around homes in water-holding containers and bites predominantly in daylight, although biting can occur beyond simple clock rules. Uncovered tanks, coolers, buckets, discarded tyres, construction sites and interrupted water supply that encourages household storage can sustain breeding. Living in an affected neighbourhood, travel to an outbreak area and caring for a viraemic person without mosquito protection raise exposure, but ordinary touch, food sharing and respiratory contact do not spread chikungunya.
Most exposed people are susceptible unless they have relevant immunity. Risk of a complicated clinical course is higher in neonates exposed around maternal viraemia, infants, older adults and patients with diabetes, hypertension, cardiovascular, renal, pulmonary or neurological disease. Frailty, dehydration, poor oral intake and limited access to reassessment compound physiological risk. Pregnancy does not necessarily make every maternal infection severe, but viraemia close to delivery creates a specific risk of vertical transmission and neonatal illness. Caesarean birth has not been shown to eliminate that risk.
Persistent musculoskeletal symptoms are more often described with older age, severe initial joint disease, pre-existing osteoarthritis or inflammatory disease and substantial acute functional impairment, but prediction is imperfect. Do not tell a patient that chronic arthritis is inevitable. Likewise, rheumatoid factor or anti-CCP positivity requires interpretation rather than automatic attribution to chikungunya. Household prevention should focus on weekly source reduction, covered water, repellents, clothing, screens and mosquito protection for the febrile patient. Fogging alone is incomplete because it does not remove larval habitats or guarantee sustained vector control.
Diagnosis
Diagnosis integrates syndrome, illness day, local transmission and appropriately timed testing. A surveillance definition supports counting; it is not a substitute for bedside assessment, severity triage or investigation of alternatives.
History
Establish the exact day of fever onset, travel and local outbreak context. Characterise joint pain by symmetry, swelling, morning stiffness, small- versus large-joint involvement and ability to walk, feed, work or perform self-care. Ask about rash, headache, myalgia, vomiting, abdominal pain, bleeding, reduced urine, breathlessness, chest pain, confusion, weakness and visual symptoms. Record pregnancy and gestation, recent delivery, neonatal exposure, comorbidity, baseline rheumatic disease and every analgesic, steroid or antibiotic already taken.
Examination
Measure temperature, pulse, blood pressure, respiratory rate, oxygen saturation, perfusion, hydration and mental state. Inspect skin and mucosa for rash or bleeding and assess joints for tenderness, effusion, synovitis and range of movement. Look for oedema, jaundice, lymphadenopathy and focal infection. Examine cardiovascular, respiratory, abdominal and neurological systems when symptoms or risk factors warrant. In pregnancy assess obstetric wellbeing; a symptomatic neonate needs paediatric evaluation.
Investigations
CBC, haematocrit, renal and liver indices, glucose and urinalysis are selected by severity and differential, not ordered ritualistically. RT-PCR is useful during early viraemia; NCVBDC describes detection during approximately the first week. IgM becomes more informative after that window, while paired IgG demonstrating a fourfold rise can support recent infection. A negative early antibody test does not exclude disease, and persisting IgM can complicate attribution. Test simultaneously for dengue, malaria or other serious local alternatives when indicated. ECG, troponin, imaging, CSF or organ-specific tests belong to atypical or severe pathways.
Differential Diagnosis
Dengue is the most consequential overlap. Both illnesses can cause fever, headache, myalgia, rash, leucopenia and thrombocytopenia; arthralgia and arthritis may dominate chikungunya, while dengue warning signs, plasma leakage, haemoconcentration, progressive thrombocytopenia and clinically significant bleeding redirect management. The distinction is not reliable from one symptom, and co-infection is possible. Until dengue is reasonably excluded, avoid aspirin and other NSAIDs and assess the patient serially rather than using an early reassuring platelet count.
Malaria must be tested according to local epidemiology and severity because falciparum infection can deteriorate quickly. Scrub typhus may show an eschar hidden in axillae, groin, inframammary folds or waistband areas, but absence of eschar does not exclude it. Leptospirosis is supported by floodwater or animal-urine exposure, conjunctival suffusion, jaundice, kidney injury or pulmonary haemorrhage. Enteric fever, acute HIV, influenza, COVID-19, measles, rubella and other viral exanthems depend on age and exposure. Bacterial sepsis and meningitis remain urgent alternatives when physiology or focal signs are concerning.
After fever resolves, persistent joint symptoms require a second differential. Reactive arthritis, rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, crystal arthritis, septic arthritis, osteoarthritis and medication-related pain can coexist or be mislabelled as post-chikungunya disease. A hot monoarthritis requires aspiration and sepsis exclusion rather than reassurance based on past chikungunya. Reopen the diagnosis if fever persists, pain is focal and escalating, inflammatory markers remain unexpectedly high, new organ dysfunction appears, tests conflict, or treatment response does not match the proposed phase.
Management
Triage comes before the label. Stabilise airway, breathing and circulation, check glucose, assess hydration and identify bleeding, shock, neurological change, myocarditis, respiratory failure, renal injury or decompensated comorbidity. Most uncomplicated patients can receive ambulatory care with rest balanced by gentle activity, adequate oral fluid, paracetamol within a current age- and liver-appropriate limit, and a defined review point. WHO 2025 suggests protocolised oral hydration for non-severe arboviral illness; intravenous fluid is not automatically superior when a patient can drink.
During acute undifferentiated arboviral disease, do not use aspirin or other NSAIDs. WHO recommends against NSAIDs at this stage irrespective of illness severity because dengue-related bleeding may not yet be excluded; it permits consideration only when chikungunya is confirmed and the clinician judges inflammatory benefit to outweigh individual harms. Routine systemic corticosteroid is also discouraged in acute non-severe or severe arboviral disease. Antibiotics do not treat chikungunya and should be reserved for a supported bacterial co-infection, not prescribed because fever persists for several days.
Post-acute care starts with phenotype and function. Confirm whether there is synovitis, tenosynovitis, neuropathic pain or mechanical limitation; encourage paced mobilisation and rehabilitation. Persistent inflammatory arthritis may need clinician-supervised NSAID treatment after contraindication review, and selected severe disease may require rheumatology-directed corticosteroid or DMARD therapy. NCVBDC itself notes limited, heterogeneous evidence for DMARDs. Review pain, swelling, gait, sleep, mood and work participation. Escalation without reassessing infection, alternate rheumatic disease and medication toxicity is unsafe.
Prescribing Information
Paracetamol is the usual initial antipyretic and analgesic, but a safe prescription requires age or weight, liver function, nutrition, alcohol history, concurrent combination products and a maximum daily dose taken from the current local formulary. Avoid duplicating paracetamol across fever tablets and cold remedies. Tepid measures may improve comfort; forced cold bathing is unnecessary. Opioids are not routine treatment for uncomplicated chikungunya, and tramadol carries sedation, interaction and seizure risks. Exact older dose ladders should not be copied into care without present-day formulary verification.
Aspirin is inappropriate for acute suspected arboviral fever. Ibuprofen, diclofenac, naproxen and other NSAIDs should be withheld until dengue and clinically important bleeding risk have been addressed. If a clinician later selects an NSAID for confirmed post-acute inflammation, check pregnancy, kidney function, dehydration, ulcer or bleeding history, anticoagulants, hypertension, heart failure and interacting drugs; use the lowest effective exposure and state stop criteria. Gastroprotection is individualized. Ranitidine recommendations in the 2023 document are not a current prescribing default and illustrate why guideline age must be disclosed.
Systemic corticosteroid should not be used simply to shorten acute fever or pain. Specialist-directed use for persistent inflammatory disease requires infection exclusion, glucose and blood-pressure monitoring, psychiatric and gastrointestinal risk assessment and a taper plan. DMARDs require diagnostic confirmation, pregnancy counselling, baseline blood counts and liver or renal tests, infection screening and ongoing monitoring. There is no routine antiviral or antibiotic course. Vaccine availability and recommendations vary internationally and continue to evolve; this guide makes no Indian individual vaccination recommendation and directs clinicians to current national immunisation policy.
When to Refer
Arrange urgent hospital assessment for haemodynamic instability, bleeding, persistent vomiting, inability to drink, reduced urine, hypoxaemia, respiratory distress, chest pain, arrhythmia, altered consciousness, seizure, focal neurological deficit or rapidly worsening weakness. A frail older person can deteriorate without dramatic fever. Suspected myocarditis, encephalitis, hepatitis, acute kidney injury or bacterial co-infection needs organ-specific investigation and monitoring. Transfer should not wait for a confirmatory chikungunya result when physiology is unsafe.
Refer high-risk infants and neonates promptly, particularly following maternal fever around delivery. In pregnancy, seek obstetric review for uterine contractions, labour, fetal-heart abnormality, reduced fetal movement, bleeding or maternal deterioration. The delivery plan belongs to obstetric and neonatal teams; caesarean section is not a proven method of preventing vertical chikungunya transmission. Paediatric referral is appropriate for poor feeding, lethargy, persistent crying, blistering eruption, seizure, respiratory signs or dehydration.
For musculoskeletal disease, arrange rheumatology or experienced physician review when objective inflammatory arthritis persists toward or beyond three months, symptoms are disabling despite safe first-line care, steroids cannot be tapered, DMARD therapy is being considered, or the pattern suggests an alternate inflammatory disorder. Ophthalmic symptoms, neuropathy or focal weakness need corresponding specialist assessment. Public-health notification and outbreak referral follow current state and NCVBDC pathways. Send onset date, residence or travel, test type and date, severity and suspected cluster information rather than an unqualified positive label.
Red Flags
Shock or evolving dengue must never be missed because a patient appears to have classic chikungunya joint pain. Cold extremities, delayed capillary refill, postural collapse, narrowing pulse pressure, hypotension, mucosal bleeding, haematemesis, melaena, severe abdominal pain, persistent vomiting, drowsiness or reduced urine require urgent reassessment. A normal platelet count early in illness is not a discharge guarantee. Excess intravenous fluid can also harm patients with myocarditis, heart failure or a different capillary-leak illness, so resuscitation needs repeated response assessment.
Neurological red flags include confusion, neck stiffness, seizure, reduced consciousness, new weakness, ataxia, cranial-nerve symptoms or severe persistent headache. Chest pain, disproportionate tachycardia, syncope, new heart failure or arrhythmia raises myocarditis concern. Dyspnoea, hypoxaemia or pulmonary oedema needs immediate evaluation. Marked jaundice, rapidly rising creatinine, severe hypoglycaemia or progressive cytopenia should not be dismissed as routine viral change. In neonates, poor feeding, temperature instability, apnoea, lethargy, seizures or extensive skin disease are emergencies.
Persistent-joint red flags are different: one intensely hot swollen joint, inability to bear weight, fever recurrence, destructive imaging, neurological deficit or an immunosuppressed state requires infection or another diagnosis to be excluded. New visual loss or painful photophobia demands eye assessment. Medication hazards include gastrointestinal bleeding, reduced urine after NSAID use, paracetamol overdose, steroid-induced hyperglycaemia or infection, and unmonitored DMARD toxicity. Safety-net advice should state the receiving facility and timescale, not merely say to return if worse.
Indian Clinical Context
NCVBDC's 2023 national guideline is the principal Indian clinical anchor. It describes an NCVBDC-supported network of sentinel surveillance hospitals linked to apex referral laboratories, with IgM MAC-ELISA supplied for programme testing. Access and turnaround remain local questions: clinicians should identify the actual designated laboratory, specimen transport requirements and reporting route rather than promise universal same-day testing. Suspected clusters require coordination with district surveillance and vector-control teams because an individual prescription does not interrupt transmission.
The Indian monsoon differential is crowded. Dengue, malaria, leptospirosis, scrub typhus and enteric fever may circulate together, and early syndromic overlap is substantial. The safest pathway is parallel testing guided by illness day and epidemiology, repeated physiological assessment and antimicrobial stewardship. Antibiotics neither prevent chronic chikungunya pain nor treat the virus. Community advice should focus on weekly emptying and scrubbing of water containers, securely covered storage, solid-waste removal, repellents, clothing and screens. A febrile patient should avoid mosquito bites during the first week so mosquitoes do not acquire and pass on virus.
There is a material evidence-version limitation. The 2023 document includes some exact analgesic, gastric-protection and post-acute regimens derived from older evidence, while WHO issued integrated arboviral recommendations in 2025 and acknowledges that much intervention evidence is indirect from dengue. Current Indian labels, national or state advisories and institutional formularies must therefore be reconciled rather than blended silently. This draft does not assert a live all-India case count, uniform laboratory availability, routine national vaccine access or superiority of one DMARD. Such claims require dated programme evidence and organizational clinical approval.
NMC Competency Mapping
The 2024 NMC microbiology curriculum maps chikungunya most directly to MI8.4, covering arboviral and vector-borne infections including dengue and chikungunya, with MI8.8 supporting prevention and infection-control principles. General Medicine integration includes assessment of acute fever, hydration, shock and organ dysfunction. Community Medicine adds surveillance, outbreak investigation, vector control and risk communication. The mapping defines undergraduate learning outcomes; it does not authorize independent management of severe arboviral disease or prescription of immunosuppression.
A competent learner should explain chikungunya virus, Aedes transmission and the human-mosquito-human cycle; distinguish acute, post-acute and chronic phases; obtain travel, outbreak, pregnancy and comorbidity history; and assess joint pattern and functional effect. Learners should compare chikungunya with dengue, malaria, leptospirosis, scrub typhus, reactive arthritis and bacterial sepsis without relying on a single symptom. They should recognise neonatal exposure around delivery and atypical neurological, cardiac, renal, hepatic or respiratory disease.
Laboratory competence means selecting RT-PCR early and serology later, interpreting negative and persisting-antibody results in relation to illness day, and understanding why a surveillance case definition differs from a clinical diagnosis. Management competence includes oral hydration, safe fever relief, avoidance of NSAIDs until dengue is addressed, antimicrobial stewardship, escalation for organ dysfunction and structured follow-up for persistent arthritis. Prevention competence includes source reduction, personal bite protection and prompt notification. Independent DMARD use, obstetric decision-making and outbreak leadership require supervision and current policy.
Key Exam Pearls for NEET PG
Chikungunya virus is an alphavirus in the Togaviridae family, transmitted mainly by Aedes aegypti and Aedes albopictus. The classic presentation is abrupt fever with severe, often bilateral and symmetrical polyarthralgia; rash and joint swelling may occur. Dengue is the crucial early mimic. More prominent arthritis favours chikungunya, while plasma leakage, progressive haemoconcentration and significant bleeding support dengue, but clinical separation is imperfect and co-infection occurs. Do not give an NSAID merely because joint pain is dramatic while dengue remains possible.
Testing follows time. Viral RNA detection by RT-PCR is most useful during early viraemia, approximately the first week; IgM becomes more useful thereafter, and paired IgG with a fourfold rise supports recent infection. An early negative IgM does not exclude chikungunya. IgM may persist, so positivity without a compatible new illness is not proof of incident disease. Virus isolation is specialized and slow. Severe thrombocytopenia is less characteristic than in dengue, but no CBC pattern is diagnostic.
Treatment is supportive because no routine specific antiviral is established. Encourage oral fluid when feasible, use paracetamol safely, avoid routine acute corticosteroids and avoid unnecessary antibiotics. Persistent inflammatory joint disease requires phenotype-based reassessment; chronic post-chikungunya symptoms are not synonymous with rheumatoid arthritis. High-risk groups include neonates exposed around maternal viraemia, older adults and people with significant comorbidity. Aedes source reduction and bite prevention remain central, and the febrile patient should avoid mosquito exposure during the first week.
Frequently Asked Questions
How can chikungunya be distinguished from dengue during the first few days?
Prominent bilateral joint pain or arthritis supports chikungunya, whereas plasma leakage, haemoconcentration, progressive thrombocytopenia and clinically important bleeding support dengue. The overlap is too great for one symptom to decide safely, and co-infection is possible. Use illness-day-appropriate tests, serial vital signs, hydration and bleeding assessment, and withhold aspirin or other NSAIDs until dengue has been reasonably excluded.
Which chikungunya laboratory test is most useful at each stage of illness?
RT-PCR is most useful during early viraemia, broadly the first week after symptom onset. IgM becomes more informative after that window; paired IgG demonstrating a fourfold rise can support recent infection. A negative early antibody result does not exclude chikungunya, while persisting IgM can reflect an earlier infection. Always record onset date, specimen date and assay rather than reporting only positive or negative.
Should persistent joint pain after chikungunya automatically be treated with steroids or DMARDs?
No. Reassess whether pain reflects active synovitis, tenosynovitis, mechanical disease, neuropathic symptoms, deconditioning or another inflammatory arthritis. Begin with function, rehabilitation and appropriately selected analgesia. Steroid or DMARD treatment requires experienced assessment, infection exclusion, baseline and ongoing safety monitoring, and recognition that NCVBDC describes the supporting DMARD evidence as limited and heterogeneous.
What should a person with suspected chikungunya do to reduce household transmission?
Seek clinical assessment, especially if pregnant, very young, older, comorbid or physiologically unwell. During the first week, use repellent, clothing, screens or nets to prevent mosquitoes biting the febrile person and carrying virus onward. Household members should empty and scrub water containers weekly, cover stored water and remove discarded containers. These measures reduce risk but do not replace district outbreak action.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic